BM

Bomi Minoo Gagrat

Director Director DIN 00043320
DIN 00043320 First appointment Sep 1998 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Sep 1998
Shareholding value β€’β€’β€’β€’ Premium profile

About Bomi Minoo Gagrat

Data last updated:

Bomi Minoo Gagrat was a Director at Pfizer Limited (1998–2012) and Director at Duchem Laboratories Limited (from 1999). The companies operate in Pharma.

DIN 00043320
Primary Designation Director
Industry Pharma
First Appointment 29 Sep 1998
Oldest Company Age 68 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Pfizer Limited L24231MH1950PLC008311
Director29 Sep 19981950₹2,454 Cr (FY 2025)Active
Duchem Laboratories Limited U74300MH1958PLC011117
Director25 Jun 19991958Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Duchem Laboratories Limited
Pfizer Limited
Premium access

Shareholding and investment profile for Bomi Minoo Gagrat

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bomi Minoo Gagrat

Bomi Minoo Gagrat was first appointed on 29 Sep 1998 as Director at Pfizer Limited. The most recent appointment on record is 25 Jun 1999 at Duchem Laboratories Limited.

Bomi Minoo Gagrat held 2 earlier board appointments: Pfizer Limited (Director, 29 Sep 1998 to 21 May 2012); Duchem Laboratories Limited (Director, from 25 Jun 1999).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available